Buy Ranbaxy on all declines: Gujral

Excerpts from Closing Bell on CNBC-TV18 Watch the full show » RELATED NEWS Stock to watch: Godrej Consumer, Nicolas Piramal, Divis Lab Brokers bullish on NTPC, Glenmark, Tata Power Buy Ranbaxy, target of Rs 644: IL&FS Investsmart ALSO READ See previous views by Ashwani Gujral See what other Experts & Brokerages are saying about Ranbaxy Labs See messages about Ranbaxy Labs Ranbaxy Labs BSE | NSE 13/02/12 Are Mutual Funds betting on Ranbaxy Labs? Other Stocks in this news Dr Reddys Laboratories |

Technical Analyst, Ashwani Gujral is of the view that Ranbaxy Laboratories is doing very well. So, people can go long on that on all declines.

Gujral told CNBC-TV18, "In pharma, Ranbaxy is doing very well. So, people can go long on that on all declines. Lupin is doing very well; Dr Reddys Laboratories is doing quite well. These are the two or three stocks that are showing strength even in weak markets."

Share Price Movement During The Last 12 Months
Period	Price	Latest Price	Gain/Loss (Rs.)	% Gain/Loss
3-Days	518.90	526.40	7.50	1.45
5-Days	514.05	526.40	12.35	2.40
7-Days	528.65	526.40	-2.25	-0.43
15-Days	498.25	526.40	28.15	5.65
1-Month	474.95	526.40	51.45	10.83
3-Month	434.95	526.40	91.45	21.03
6-Month	397.95	526.40	128.45	32.28
9-Month	414.05	526.40	112.35	27.13
1-Year	380.25	526.40	146.15	38.44